Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Gliknik is raising $12,000,003.00 in new funding. Sources indicate as part of senior management Chairman and Chief Executive Officer, David Block played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gliknik

Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with cancer and immune disorders. The Gliknik team combines scientific expertise with business acumen and deep experience in the biopharmaceutical industry. Gliknik currently has two novel drugs in clinical trials and others being advanced preclinically. The company has a shared commitment to always trying to do the right thing. Inspired by a wish to apply cutting-edge science to ease human suffering, the company’s mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders.

To learn more about Gliknik, visit http://www.gliknik.com/

Contact:
David Block, Chairman and Chief Executive Officer
410-685-0662

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved